Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of HRS-8427 in Subjects With Renal Impairment
NCT07070375Phase 1Completed
- Sponsor
- Hengrui
- Start
- Apr 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HRS-8427 in Gram-negative bacterial infection (5 arms), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration at 4 days, Area Under the Curve from time zero to last measurable concentration at 4 days and 3 more. Started Apr 2023; status: completed.
02
Drugs
HRS-8427
03
Conditions
Gram-negative bacterial infection
Beyond the preview
Go deeper on NCT07070375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07070375.